On August 30, 2018 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), reported that John P. Butler, President and Chief Executive Officer, will participate in the following investor conferences (Press release, Akebia, AUG 30, 2018, View Source [SID1234529193]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Thursday, September 6, 2018, at 1:45 p.m. Eastern Time, at the St. Regis New York Hotel.

The 16th Annual Morgan Stanley Global Healthcare Conference on Friday, September 14, 2018, at 10:30 a.m. Eastern Time, at the Grand Hyatt New York.

A live webcast of the presentations will be available on the company’s website at www.akebia.com. To access, please log onto the Akebia website at least 15 minutes prior to the webcasts to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Akebia’s website following the conferences.

On August 30, 2018 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, reported that Stephen Yoder, President and Chief Executive Officer, will present at the 20th Annual Rodman & Renshaw Global Investment Conference on Wednesday, September 5th at 12:05PM EDT at the St. Regis New York Hotel in New York (Press release, Pieris Pharmaceuticals, AUG 30, 2018, https://ir.pieris.com/news/detail/599/pieris-pharmaceuticals-to-present-at-the-20th-annual-rodman-renshaw-global-investment-conference [SID1234529215]). A webcast of the Company’s presentation will be available at this link.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 30, 2018 Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, reported that Steven A. Shallcross, Interim Chief Executive Officer & Chief Financial Officer, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, in New York City on Thursday, September 6, 2018, at 9:35 a.m. ET (Press release, Synthetic Biologics, AUG 30, 2018, View Source [SID1234529194]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the web at View Source After the presentation, a replay will be archived and accessible for 60 days on Synthetic Biologics’ website, www.syntheticbiologics.com.

On August 30, 2018 GTx, Inc. (Nasdaq: GTXI) reported that Robert J. Wills, PhD, Executive Chairman, and other senior executive management team members will present a company overview at the Baird 2018 Global Healthcare Conference on Thursday, September 6, 2018 at 9:05 am ET in New York (Press release, GTx, AUG 30, 2018, View Source;p=irol-newsArticle&ID=2365454 [SID1234529177]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A simultaneous webcast of the presentation can be accessed by visiting the investor relations section of the GTx website at View Source A replay of the presentation will also be available and archived on the site for 30 days.

On August 30, 2018 vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, reported it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, vTv Therapeutics, AUG 30, 2018, View Source [SID1234529195]).The conference is being held September 4-6, 2018, at The St. Regis Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

vTv management will provide an overview of the company’s business during the live presentation at 1:45pm ET on September 6, 2018 in the Fontainebleau Foyer (2nd floor).

A live webcast of the presentation can be accessed here and will be archived for 30 days following the presentation at www.vtvtherapeutics.com.